Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 40

1.

The effect of vortioxetine on overall patient functioning in patients with major depressive disorder.

Florea I, Loft H, Danchenko N, Rive B, Brignone M, Merikle E, Jacobsen PL, Sheehan DV.

Brain Behav. 2017 Feb 2;7(3):e00622. doi: 10.1002/brb3.622. eCollection 2017 Mar.

2.

Understanding the Relationship between Trauma Exposure and Depression among Adolescents after Earthquake: The Roles of Fear and Resilience.

Zhou X, Wu X, An Y.

Front Psychol. 2016 Dec 26;7:2044. doi: 10.3389/fpsyg.2016.02044. eCollection 2016.

3.

Intrinsic inter-network brain dysfunction correlates with symptom dimensions in late-life depression.

Li W, Wang Y, Ward BD, Antuono PG, Li SJ, Goveas JS.

J Psychiatr Res. 2017 Apr;87:71-80. doi: 10.1016/j.jpsychires.2016.12.011. Epub 2016 Dec 12.

PMID:
28017917
4.

The Impact of Residual Symptoms in Major Depression.

Israel JA.

Pharmaceuticals (Basel). 2010 Aug 3;3(8):2426-2440. Review.

5.

Clinical predictors of depression treatment outcomes in patients with coronary heart disease.

Carney RM, Freedland KE, Steinmeyer BC, Rubin EH, Rich MW.

J Psychosom Res. 2016 Sep;88:36-41. doi: 10.1016/j.jpsychores.2016.07.011. Epub 2016 Jul 19.

PMID:
27521651
6.

Predictors and Moderators of Remission With Aripiprazole Augmentation in Treatment-Resistant Late-Life Depression: An Analysis of the IRL-GRey Randomized Clinical Trial.

Kaneriya SH, Robbins-Welty GA, Smagula SF, Karp JF, Butters MA, Lenze EJ, Mulsant BH, Blumberger D, Anderson SJ, Dew MA, Lotrich F, Aizenstein HJ, Diniz BS, Reynolds CF 3rd.

JAMA Psychiatry. 2016 Apr;73(4):329-36. doi: 10.1001/jamapsychiatry.2015.3447.

7.

Using patient self-reports to study heterogeneity of treatment effects in major depressive disorder.

Kessler RC, van Loo HM, Wardenaar KJ, Bossarte RM, Brenner LA, Ebert DD, de Jonge P, Nierenberg AA, Rosellini AJ, Sampson NA, Schoevers RA, Wilcox MA, Zaslavsky AM.

Epidemiol Psychiatr Sci. 2017 Feb;26(1):22-36. doi: 10.1017/S2045796016000020. Epub 2016 Jan 26.

8.

A randomized, placebo-controlled pilot trial of the delta opioid receptor agonist AZD2327 in anxious depression.

Richards EM, Mathews DC, Luckenbaugh DA, Ionescu DF, Machado-Vieira R, Niciu MJ, Duncan WC, Nolan NM, Franco-Chaves JA, Hudzik T, Maciag C, Li S, Cross A, Smith MA, Zarate CA Jr.

Psychopharmacology (Berl). 2016 Mar;233(6):1119-30. doi: 10.1007/s00213-015-4195-4. Epub 2016 Jan 4.

9.

Anxiety and anxious-depression in Parkinson's disease over a 4-year period: a latent transition analysis.

Landau S, Harris V, Burn DJ, Hindle JV, Hurt CS, Samuel M, Wilson KC, Brown RG.

Psychol Med. 2016 Feb;46(3):657-67. doi: 10.1017/S0033291715002196. Epub 2015 Oct 23.

10.

The course of depression in late life as measured by the Montgomery and Asberg Depression Rating Scale in an observational study of hospitalized patients.

Borza T, Engedal K, Bergh S, Benth JŠ, Selbæk G.

BMC Psychiatry. 2015 Aug 5;15:191. doi: 10.1186/s12888-015-0577-8.

11.

Predictors of anxiety recurrence in the Coordinated Anxiety Learning and Management (CALM) trial.

Taylor JH, Jakubovski E, Bloch MH.

J Psychiatr Res. 2015 Jun;65:154-65. doi: 10.1016/j.jpsychires.2015.03.020. Epub 2015 Apr 4.

12.

The two-year course of late-life depression; results from the Netherlands study of depression in older persons.

Comijs HC, Nieuwesteeg J, Kok R, van Marwijk HW, van der Mast RC, Naarding P, Voshaar RC, Verhaak P, de Waal MW, Stek ML.

BMC Psychiatry. 2015 Feb 12;15:20. doi: 10.1186/s12888-015-0401-5.

13.

Safety, tolerability, and clinical effect of low-dose buprenorphine for treatment-resistant depression in midlife and older adults.

Karp JF, Butters MA, Begley AE, Miller MD, Lenze EJ, Blumberger DM, Mulsant BH, Reynolds CF 3rd.

J Clin Psychiatry. 2014 Aug;75(8):e785-93. doi: 10.4088/JCP.13m08725.

14.

Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.

Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M; Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University., Antony MM, Bouchard S, Brunet A, Flament M, Grigoriadis S, Mendlowitz S, O'Connor K, Rabheru K, Richter PM, Robichaud M, Walker JR.

BMC Psychiatry. 2014;14 Suppl 1:S1. doi: 10.1186/1471-244X-14-S1-S1. Epub 2014 Jul 2. Review.

15.

Prognostic subgroups for citalopram response in the STAR*D trial.

Jakubovski E, Bloch MH.

J Clin Psychiatry. 2014 Jul;75(7):738-47. doi: 10.4088/JCP.13m08727.

16.

Differential impact of anxiety symptoms and anxiety disorders on treatment outcome for psychotic depression in the STOP-PD study.

Davies SJ, Mulsant BH, Flint AJ, Rothschild AJ, Whyte EM, Meyers BS; STOP PD Study Group..

Compr Psychiatry. 2014 Jul;55(5):1069-76. doi: 10.1016/j.comppsych.2014.02.001. Epub 2014 Feb 12.

17.

Dynamic prediction of treatment response in late-life depression.

Joel I, Begley AE, Mulsant BH, Lenze EJ, Mazumdar S, Dew MA, Blumberger D, Butters M, Reynolds CF 3rd; IRL GREY Investigative Team..

Am J Geriatr Psychiatry. 2014 Feb;22(2):167-76. doi: 10.1016/j.jagp.2012.07.002. Epub 2013 Feb 6.

18.

The effectiveness of individual interpersonal psychotherapy as a treatment for major depressive disorder in adult outpatients: a systematic review.

van Hees ML, Rotter T, Ellermann T, Evers SM.

BMC Psychiatry. 2013 Jan 11;13:22. doi: 10.1186/1471-244X-13-22. Review.

19.

A lifespan view of anxiety disorders.

Lenze EJ, Wetherell JL.

Dialogues Clin Neurosci. 2011;13(4):381-99. Review.

20.

Insomnia and objectively measured sleep disturbances predict treatment outcome in depressed patients treated with psychotherapy or psychotherapy-pharmacotherapy combinations.

Troxel WM, Kupfer DJ, Reynolds CF 3rd, Frank E, Thase ME, Miewald JM, Buysse DJ.

J Clin Psychiatry. 2012 Apr;73(4):478-85. doi: 10.4088/JCP.11m07184. Epub 2011 Nov 29.

Supplemental Content

Support Center